AI EQUITY RESEARCH FOR WORKING INVESTORS
You shouldn't have to judge a stock alone.
A panel of legendary-investor archetypes debates each stock — bull case, bear case, key levels — so you understand the thesis before you decide. Oslo Børs & S&P 500 today — expanding across the Nordics soon.
Oslo Børs & S&P 500 today — expanding across the Nordics soon · Analysis, not advice
Latest analysis
A panel of legendary investors debates each stock — disagreement surfaced, not collapsed — with the key support and resistance levels.
- Apple Inc.AAPLAug 22, 2026⚡ verdict changedSix investing archetypes weigh Apple at $309.35 — all agree the moat is world-class, but none see a reason to buy now. The stock sits trapped between a breakout trigger at $317 and support near $298, with a CEO transition, memory-cost headwinds, and regulatory risk keeping conviction in check. The verdict is BALANCED: wait for price or the new CEO to give a clear signal.WaitJul 1$294.49+7.1%BalancedJul 11$315.32+5.8%WaitJul 18$333.74new callWaitJul 25$333.02holdingWaitAug 1$308.91holdingWaitAug 8$313.33holdingWaitAug 15$305.93-7.3%BalancedAug 22$309.35new callOngoing
- AbbVie Inc.ABBVAug 22, 2026⚡ verdict changedAbbVie's immunology franchise is firing on all cylinders, but the stock's climb to $265 splits our panel down the middle: one analyst calls it a buy on a forward PEG of 0.80, three say it is fairly priced with no edge, and two refuse to pay a premium multiple with negative book value and $64 billion in debt. The verdict is BALANCED, with a pullback to the $238–$249 zone as the consensus trigger that would unite the panel behind a buy call.WaitAug 15$249.46+6.2%BalancedAug 22$264.96new callOngoing
- Adobe Inc.ADBEAug 22, 2026Six archetypes examine Adobe at $275: a wide-moat software franchise trading at 10.6x forward earnings with $10.3 billion in free cash flow and a $25 billion buyback. Three see a deep-value bargain, two want a technical breakout above $285 before committing, and one DCF model suggests the stock is still slightly overvalued — but the entire panel agrees the AI disruption question will decide the outcome.BuyAug 22$275.30new callOngoing
- Aker ASAAKERAug 22, 2026Six distinct investing frameworks converge on the same conclusion for Aker ASA at 1,488 NOK: the stock has run past every analyst target, erased its historical NAV discount, and prices in an AI future that declining earnings do not support. The debate among the panel is not direction but depth, with fair-value estimates spanning 900 to 1,300 NOK, and whether Nscale can deliver real revenue before the narrative exhausts itself.BalancedAug 8kr 1376+4.7%SellAug 15kr 1440new callSellAug 22kr 1488+3.3%Ongoing
- Aker BP ASAAKRBPAug 22, 2026⚡ verdict changedSix analyst frameworks assess Aker BP at 354.8 NOK: the lone bull sees 17% upside on an $80 Brent base case, the lone bear warns of classic late-cycle signals after a 46% rally, and four cautious voices see insufficient margin of safety above the consensus target of 329. The verdict is BALANCED, with the next decisive move hinging on whether price tests the 328\–336 support zone or breaks above 373.80 resistance.BalancedJul 15kr 322.30+1.7%WaitJul 18kr 327.80+3.9%BalancedJul 25kr 340.50-1.8%WaitAug 1kr 334.50new callWaitAug 8kr 330.10holdingWaitAug 15kr 345.60+6.1%BalancedAug 22kr 354.80new callOngoing
- Applied Materials, Inc.AMATAug 22, 2026⚡ verdict changedApplied Materials divides the panel: three voices see a high-quality AI-driven growth story at a reasonable PEG, while two holdouts — one objecting on price, one on the business cycle — keep the verdict at BALANCED. The next move hinges on whether the stock reclaims $516 or loses $484 on a weekly closing basis.WaitAug 15$507.18-2.9%BalancedAug 22$492.32new callOngoing
How Verdix works
Collect filings, earnings, and price action
Every ticker starts from the same public company filings, earnings results, and price/volume action — the shared factual base every archetype reasons from.
Analyze through 13 investing archetypes
Each archetype applies its own documented framework — moat quality, deep value, GARP, disruptive growth, forensic accounting, macro, and more — to those same facts.
Debate generated
The archetypes argue it out. We surface where they agree and where they clash instead of collapsing the disagreement into one score.
Consensus produced
The debate resolves into a single synthesized verdict with a stated conviction level — a reasoned synthesis, not a headcount of who agreed.
Key levels identified
Support and resistance zones plus the analyst consensus target, so you see where the stock sits today — never a trade signal.
Why Verdix
Reasoning, not rules.
Other tools score a stock against fixed checklists. Verdix asks the actual question — would a moat compounder buy this *given today's context*? — and lets the agents reason.
Disagreement surfaced, not collapsed.
Most tools give you one number. Verdix shows you the spread — the Forensic Skeptic says SELL, the Disruptive-Innovation Seeker says BUY, here's why. The debate is the product.
A considered read, not on-demand chat.
A real analysis of each stock — the kind you return to, not a noisy real-time feed. Built to become a weekly inbox habit, not another chat window.
Institutional depth, modern-AI economics.
Other tools charge NOK 500–1,400/mo for serious equity research. Modern AI + weekly batch + caching means real depth doesn't have to cost that.
Who it's for
Not enough time for filings.
A day job and 15 minutes, not an evening — reads the panel's verdict and key levels, then gets on with the week.
Playing the long game.
Wants a second opinion before adding to a position — the panel's bull case and bear case side by side before committing more capital.
Done trusting a checklist.
Already pays for a rules-based signal service or scrolls a forum for a take — wants the actual reasoning behind the call: archetypes debating it out loud.
Every verdict, on the record
An append-only public log of every verdict we publish — the date, the price at publication, and the price change during each verdict period. Nothing edited, nothing deleted.
- BalancedApple Inc.AAPLAug 22, 2026Ongoing
- BalancedAbbVie Inc.ABBVAug 22, 2026Ongoing
- BuyAdobe Inc.ADBEAug 22, 2026Ongoing
- SellAker ASAAKERAug 22, 2026Ongoing
- BalancedAker BP ASAAKRBPAug 22, 2026Ongoing
Period returns reflect the price change between two published verdict dates — stated facts from article frontmatter, not live market data. Past performance does not predict future results. Educational analysis, not investment advice.
Tell us what to cover
Tell us which stocks you want the panel to cover. We'll email you when the analysis is live.